Intestinal P‐gp activity is reduced in postmenopausal women under breast cancer therapy

Documenti analoghi

• A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
  di: Amanda Long, et al.
  Pubblicazione: (2024)
• Targeting lysine methyltransferase 2C deficiency: New frontiers in breast cancer therapy and prognosis
  di: Shuangmei Tong, et al.
  Pubblicazione: (2026)
• Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?
  di: Zhiheng Yu, et al.
  Pubblicazione: (2024)
• From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment
  di: Ana Flávia Mendes Batista, et al.
  Pubblicazione: (2025)
• Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer
  di: Harshita Singhai, et al.
  Pubblicazione: (2026)